Summary
Roughly a decade ago, longevity burst into headlines as the next big thing in biotech. But the hype fizzled not because of a lack of robust science, said Sergey Jakimov, managing partner at LongeVC, a venture capital firm focused on biotech and longevity investing. Rather, start-ups failed due to an…
Source: BioSpace
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
